These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38238963)

  • 21. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy.
    Stolte B; Bois JM; Bolz S; Kizina K; Totzeck A; Schlag M; Kleinschnitz C; Hagenacker T
    Eur J Neurol; 2020 Dec; 27(12):2586-2594. PubMed ID: 32781490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability of hand-held dynamometry in spinal muscular atrophy.
    Merlini L; Mazzone ES; Solari A; Morandi L
    Muscle Nerve; 2002 Jul; 26(1):64-70. PubMed ID: 12115950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.
    Trucco F; Ridout D; Scoto M; Coratti G; Main ML; Muni Lofra R; Mayhew AG; Montes J; Pane M; Sansone V; Albamonte E; D'Amico A; Bertini E; Messina S; Bruno C; Parasuraman D; Childs AM; Gowda V; Willis T; Ong M; Marini-Bettolo C; De Vivo DC; Darras BT; Day J; Kichula EA; Mayer OH; Navas Nazario AA; Finkel RS; Mercuri E; Muntoni F;
    Neurology; 2021 Jan; 96(4):e587-e599. PubMed ID: 33067401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of Upper Limb Function and the Relationship with Gross Motor Functional and Structural Parameters in Patients with Spinal Muscular Atrophy.
    Bieniaszewska A; Sobieska M; Steinborn B; Gajewska E
    Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.
    Wadman RI; Wijngaarde CA; Stam M; Bartels B; Otto LAM; Lemmink HH; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    Eur J Neurol; 2018 Mar; 25(3):512-518. PubMed ID: 29194869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3.
    Hiebeler M; Abicht A; Reilich P; Walter MC
    J Neuromuscul Dis; 2021; 8(4):537-542. PubMed ID: 33682724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy.
    Lilien C; Reyngoudt H; Seferian AM; Gidaro T; Annoussamy M; Chê V; Decostre V; Ledoux I; Le Louër J; Guemas E; Muntoni F; Hogrel JY; Carlier PG; Servais L;
    Ann Clin Transl Neurol; 2021 Oct; 8(10):1938-1950. PubMed ID: 34453498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen.
    Vidovic M; Freigang M; Aust E; Linse K; Petzold D; Günther R
    BMC Neurol; 2023 Jun; 23(1):216. PubMed ID: 37280513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.
    Kirschner J; Schorling D; Hauschke D; Rensing-Zimmermann C; Wein U; Grieben U; Schottmann G; Schara U; Konrad K; Müller-Felber W; Thiele S; Wilichowski E; Hobbiebrunken E; Stettner GM; Korinthenberg R
    Neuromuscul Disord; 2014 Feb; 24(2):134-42. PubMed ID: 24300782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
    Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
    J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
    Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
    J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Instruments to assess upper-limb function in children and adolescents with neuromuscular diseases: a systematic review.
    Davoli GBQ; Cardoso J; Silva GC; Moreira RFC; Mattiello-Sverzut AC
    Dev Med Child Neurol; 2021 Sep; 63(9):1030-1037. PubMed ID: 33834485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis.
    Pascual-Morena C; Martínez-Vizcaíno V; Cavero-Redondo I; Martínez-García I; Moreno-Herráiz N; Álvarez-Bueno C; Saz-Lara A
    Pharmacotherapy; 2024 Jan; 44(1):97-105. PubMed ID: 37574770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing perspectives of disease burden and clinically meaningful changes using the Spinal Muscular Atrophy Health Index in adolescents and young adults.
    Mazzella A; Cruz R; Belter L; Curry M; Dilek N; Zizzi C; Heatwole C; Jarecki J
    Muscle Nerve; 2022 Sep; 66(3):276-281. PubMed ID: 35616549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.